Shanghai Baiqu Biomedical Technology Co., Ltd. announced that it has received $2,900,000 in funding led by Guangzhou Kingmed Diagnostics Group Co., Ltd. on January 3, 2023. The transaction included participation from Qiming Weichuang Venture Capital Management (Shanghai) Company Limited.
Guangzhou Kingmed Diagnostics Group Co., Ltd.
Equities
603882
CNE100002VW1
Healthcare Facilities & Services
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
38.35 CNY | -4.84% | +0.66% | -38.71% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.71% | 2.46B | |
-18.58% | 8.3B | |
+47.25% | 3.78B | |
-8.58% | 2.47B | |
-10.06% | 2.31B | |
-5.44% | 1.95B | |
-17.79% | 1.59B | |
-40.78% | 1.21B | |
+6.69% | 1.1B | |
-23.31% | 931M |
- Stock Market
- Equities
- 603882 Stock
- News Guangzhou Kingmed Diagnostics Group Co., Ltd.
- Shanghai Baiqu Biomedical Technology Co., Ltd. announced that it has received $2.9 million in funding from Guangzhou Kingmed Diagnostics Group Co., Ltd., Qiming Weichuang Venture Capital Management Company Limited